48 results on '"Wesseler C"'
Search Results
2. Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors
3. 1325P Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP registry real-world cohort (AIO-TRK-0315)
4. 1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
5. P74.02 Treatment Patterns of EGFR mt+ NSCLC IV pts: Real World Data of the NOWEL Network
6. P33.20 Evaluation of Combined Biomarker of Response to Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer
7. 1246P Hybrid capture-based assays in primary diagnostics of NSCLC patients: Results from the NEOlung study
8. 1912TiP NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery
9. Treatment patterns of EGFR mt+ NSCLC IV patients: Real world data of the NOWEL network
10. Treatment patterns of EGFR mt+ NSCLC IV pts: Real-world data of the NOWEL network
11. Ungewöhnliche disseminierte Metastasierung des malignen Pleuramesothelioms bei stabilem Lokalbefund unter Immuntherapie. 2 Fallberichte mit Lungen- und Hirnmetastasen.
12. Risk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients
13. Risk of not receiving 2nd line therapy is high in EGFR mt+ patients: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients
14. P1.01-82 Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts
15. Risk of not receiving second-line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts
16. 163P The influence of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ patients on OS and PFS: Results of the NOWEL network
17. Impact on OS and PFS of 2nd and 3 rd Generation TKI in EGFR mt+ and ALK+ patients: Results of the NOWEL network
18. Immuncheckpointinhibition als Therapieoption bei einschmelzenden Nichtkleinzelligen Lungenkarzinomen
19. Neues zur molekular gezielten Therapie
20. P3.01-038 Impact on OS and PFS of 2nd and 3rd Generation TKI in EGFR Mt+ and ALK+ Patients: Results of the NOWEL Network
21. 1533P - Treatment patterns of EGFR mt+ NSCLC IV pts: Real-world data of the NOWEL network
22. Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ pts: Results of the NOWEL network
23. Erfolgreiche interventionelle Embolisation einer schweren pulmonalen Blutung bei Pulmonalarterienagenesie mit ausgeprägter Kollateralbildung
24. Design der JUNIPER Studie auf Grundlage der Phase 1 Daten zu Abemaciclib: Eine randomisierte Phase 3 Studie zum Vergleich von Abemaciclib versus Erlotinib bei NSCLC im Stadium IV mit nachgewiesener KRAS mutation
25. Das maligne epitheloide Haemangioendotheliom (EHE) der Lunge – 2 Fälle einer seltenen Tumorentität ohne etablierte Therapiestandards
26. PET – positive Herde beidseits: Oligo – metastasiert? Synchrone/Metachrone Bronchialkarzinome?
27. Identification of therapeutically targetable genomic alterations in a cohort of patients with CUP using a hybrid-capture based next generation sequencing assay
28. 1447P - Risk of not receiving second-line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts
29. 1359P - Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ pts: Results of the NOWEL network
30. 152 - Identification of therapeutically targetable genomic alterations in a cohort of patients with CUP using a hybrid-capture based next generation sequencing assay
31. 1334P PET/CT-guided immune checkpoint blocker treatment discontinuation vs treatment continuation in lung cancer long-term responders: A National Network Genomic Medicine Lung Cancer Germany (nNGM) analysis.
32. 121P Risk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients.
33. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
34. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.
35. [Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma].
36. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions.
37. Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315).
38. High In-Hospital Mortality in SARS-CoV-2-Infected Patients with Active Cancer Disease during Omicron Phase of the Pandemic: Insights from the CORONA Germany Study.
39. Is Dementia Associated with COVID-19 Mortality? A Multicenter Retrospective Cohort Study Conducted in 50 Hospitals in Germany.
40. NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.
41. The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
42. Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors.
43. Prognostic Impact of Acute Cardiovascular Events in COVID-19 Hospitalized Patients-Results from the CORONA Germany Study.
44. Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV.
45. Clinical outcome, risk assessment, and seasonal variation in hospitalized COVID-19 patients-Results from the CORONA Germany study.
46. A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
47. Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.
48. Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.